课题基金 / 基金详情

TGF Beta receptor biology in human renal cell carcinoma

TGF Beta receptor biology in human renal cell carcinoma
人肾细胞癌中的 TGF Beta 受体生物学
批准号:
7911288
负责人:
John A. Copland
金额:
$15.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2010-07-31
关键词:
AccountingAdenovirus VectorAmino AcidsAnimal ModelApoptosisAreaAttenuatedBindingBiologyCarcinogenesis MechanismCell LineCell ProliferationCell modelCell physiologyCellsClinicalConventional (Clear Cell) Renal Cell CarcinomaCytoplasmic TailDataDevelopmentDiseaseDown-RegulationEngineeringEpithelialEpithelial CellsEventGene ExpressionGenesGenomicsGoalsGrowthHealthHumanHuman CloningImageryIn VitroInhibition of Cell ProliferationInjection of therapeutic agentKidneyLigandsLinkLiteratureLocalized DiseaseMalignant - descriptorMalignant Epithelial CellMapsMeasuresMediatingMessenger RNAMetabolismMetastatic Renal Cell CancerMicrometastasisModelingMolecularNeoplasm MetastasisNude MicePathologyPathway interactionsPatientsPhenotypePhysiologyPoint MutationPrincipal InvestigatorProteinsReagentReceptor SignalingRegulationRenal Cell CarcinomaResearchResistanceResponse ElementsRetinoic Acid ReceptorRoleSamplingSentinelSignal PathwaySignal TransductionSmall Interfering RNASpecimenTGF beta type III receptorTestingTherapeuticTherapeutic InterventionTimeTranscriptional RegulationTransforming Growth Factor betaTransforming Growth Factor beta ReceptorsTretinoinTumorigenicityWorkangiogenesisauthoritybasecarcinogenesiscellular engineeringclinical materialdisease phenotypeeffective therapyefficacy testinggene repressiongene therapygenetic profilingin vivoin vivo Modelinterestkidney cellloss of functionmolecular markermutantneoplasticneoplastic cellnovelnovel therapeutic interventionprogramspromoterprotein functionreceptorreconstitutionresearch studyresponsetherapy developmenttumortumor progressiontumorigenesis

项目摘要

项目成果

John A. Copland的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC) is a major health issue. While localized disease can be cured surgically, there is no effective treatment for metastatic disease. The development of therapy awaits understanding of the molecular pathways that underlie RCC carcinogenesis. Using genomic profiling of conventional RCC patient matched specimens, we identified aberrations in the transforming growth factor beta (TGFbeta) pathway. We observed loss of type III TGFbeta receptor (TbetaR3) in all samples. This suggests that loss of TbetaR3 is an early, sentinel event in the genesis of RCC. This is the first clear demonstration linking loss of TbetaR3 to a disease state. We also observed loss of type II TGFbeta receptor (TbetaR2) in metastatic RCC's. These data suggest that aberrations in TGFbeta signaling are important in RCC carcinogenesis and progression, and are mediated through down regulation of TbetaR. We hypothesize that loss of TbetaR3 promotes RCC tumorigenesis through dysregulation of TGFbeta signaling, mediated through Smad dependent and/or independent mechanisms. Our preliminary data also support the hypothesis that TbetaR3 has growth inhibitory activity independent of TGFbeta signaling and TbetaR2. These hypotheses will be tested in models of RCC, in vitro and in vivo, through the following specific aims: 1) We will test the hypothesis that TbetaR3 inhibits cell proliferation in RCC, in vitro, through both Smad dependent and independent mechanisms. We will further test whether TbetaR3 growth inhibition is mediated through TGFbeta/TbetaR2 independent pathways through interaction with, as yet, unknown intracellular proteins. 2) We will test the hypothesis that TbetaR3 inhibits tumorigenicity in vivo, using relevant animal models of RCC. We will test the efficacy of adenoviral gene therapy targeting TbetaR. 3) We will test the hypothesis that TbetaR3 is silenced in RCC through transcriptional regulation of the TbetaR3 promoter. Completion of these studies will define the role of TbetaR3 loss in RCC carcinogenesis, the function of TbetaR3 in normal renal biology and carcinogenesis, and the mechanism of regulation of TbetaR3 in RCC biology.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
DOI: 10.18632/oncotarget.2097
发表时间: 2014-07-30
期刊: Oncotarget
影响因子: --
作者: [Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA]
通讯作者: Copland JA
DOI: 10.1021/ac402108x
发表时间: 2013-10-15
期刊: ANALYTICAL CHEMISTRY
影响因子: 7.4
作者: [Powers, Thomas W., Jones, E. Ellen, Betesh, Lucy R., Romano, Patrick R., Gao, Peng, Copland, John A., Mehta, Anand S., Drake, Richard R.]
通讯作者: Drake, Richard R.
DOI: 10.1371/journal.pone.0010696
发表时间: 2010-05-18
期刊: PloS one
影响因子: 3.7
作者: [Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA]
通讯作者: Copland JA
DOI: 10.1158/0008-5472.can-14-0210
发表时间: 2014-09-01
期刊: Cancer research
影响因子: 11.2
作者: [von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA]
通讯作者: Copland JA
11
    Modulation of cancer induced immune suppression via inhibition of SCD1
    • 批准号:
      10896572
    • 项目类别:
    • 资助金额:
      $130.18万
    • 财政年份:
      2022
    • 负责人:
      John A. Copland
    • 依托单位:
    Modulation of cancer induced immune suppression via inhibition of SCD1
    • 批准号:
      10546697
    • 项目类别:
    • 资助金额:
      $40.0万
    • 财政年份:
      2022
    • 负责人:
      John A. Copland
    • 依托单位:
    Engineered microtumor arrays for development of combination therapies
    • 批准号:
      10029690
    • 项目类别:
    • 资助金额:
      $24.39万
    • 财政年份:
      2020
    • 负责人:
      John A. Copland
    • 依托单位:
    Engineered microtumor arrays for development of combination therapies
    • 批准号:
      10442587
    • 项目类别:
    • 资助金额:
      $26.01万
    • 财政年份:
      2020
    • 负责人:
      John A. Copland
    • 依托单位:
    海外基金